MOR — Morphosys AG Share News
0.000.00%
Last trade - 00:00- €2.53bn
- €2.16bn
- €238.28m
Brief: Morphosys AG Subsidiary Constellation Pharmaceuticals Enters Into Global Licensing Agreement With Novartis
Europe Research Roundup: Meyer Burger Technology AG, SAP SE, Scor
Brief: MorphoSys AG Reports Quarterly Total Revenue Of € 95.8 Mln
Brief: Morphosys Says 9M 2022 Revenue Was Eur 196.7 Mln vs Eur 126.7 Mln
Brief: Morphosys Q3 Operating Loss Narrows To EUR 29.3 Mln
Citi, Stifel cut Morphosys after Alzheimer's drug fails to meet goal
Roche, Morphosys sink as Alzheimer's drug fails to meet goal
Roche says Alzheimer's drug fails to meet goal in trial (updated)
Brief: Morphosys Presents Preliminary Results From Phase 1/2 Study Of Tulmimetostat
Brief: Morphosys' Licensing Partner, GSK Provides Update On Contrast Phase Iii Program For Otilimab In Moderate To Severe Rheumatoid Arthritis
Deutsche Bank cuts MorphoSys to 'sell' post outlook cut, shares slide
Brief: Morphosys Preliminary Q3 Monjuvi U.S. Sales At $22.2 Mln
Europe Research Roundup: Gecina, Synthomer, Volvo
MorphoSys rises after JPM places on positive watch ahead of partner Alzheimer's study data
Morphosys rises on long-term data from lymphoma drug study
Brief: MorphoSys Presents New Long-Term Data From L-Mind Suggesting Durable Response To Treatment With Monjuvi® For Patients With R/R DLBCL
Europe Research Roundup: Adidas, Onthemarket, Softcat
Morphosys slides on $300 mln debt drawdown
German stocks - Factors to watch on August 4